These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 500299)

  • 21. Relation between middle molecules and parathyroid hormone in patients with chronic renal failure.
    Fröhling PT; Kokot F; Cernacek P; Vetter K; Kuska J; Spustova V; Kaschube I; Dzurik R
    Miner Electrolyte Metab; 1982 Jan; 7(1):48-53. PubMed ID: 7169976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of an oral sorbent (AST-120) on the clinical course of uremic peak 2a in chronic renal failure].
    Koide K; Toyama J; Inoue N; Koshikawa S; Akizawa T; Takahashi K; Hidaka S; Yamane Y; Nakao M; Ono S
    Nihon Jinzo Gakkai Shi; 1987 Aug; 29(8):1003-11. PubMed ID: 3694879
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 24. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
    Mydlík M; Derzsiová K
    Kidney Int Suppl; 2001 Feb; 78():S304-7. PubMed ID: 11169031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-2-microglobulin as a uremic toxin: the Japanese experience.
    Fujimori A
    Contrib Nephrol; 2011; 168():129-133. PubMed ID: 20938132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 27. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F
    Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Middle molecular weight substances in the cerebrospinal fluid of uremic patients.
    Sperschneider H; Spustova V; Stein G; Dzurik R
    Clin Nephrol; 1982 Jun; 17(6):298-302. PubMed ID: 7105504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival of hemodialysis patients and uremic toxin removal.
    Vanholder R; Smet RD; Glorieux G; Dhondt A
    Artif Organs; 2003 Mar; 27(3):218-23. PubMed ID: 12662205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of haemodialysate and its peptide fractions on acetylcholinesterase activity in erythrocytes from healthy subjects and patients with terminal renal failure.
    Smoleński O; Tabarowski Z; Miszta H; Dabrowski Z
    Int Urol Nephrol; 1993; 25(5):503-8. PubMed ID: 8270380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing the removal of protein-bound uremic toxins by liposome-supported hemodialysis.
    Shi Y; Wang Y; Ma S; Liu T; Tian H; Zhu Q; Wang W; Li Y; Ding F
    Artif Organs; 2019 May; 43(5):490-503. PubMed ID: 30375673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uremic toxins.
    Ringoir S; Schoots A; Vanholder R
    Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
    [No Abstract]   [Full Text] [Related]  

  • 33. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of Uremic Toxins on Apoptosis With Varying Periods of Hemodialysis.
    Hünkerler Z; Köken T; Koca B; Kahraman A
    Ther Apher Dial; 2017 Feb; 21(1):38-42. PubMed ID: 28067473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum hippurate and its excretion in conservatively treated and dialysed patients with chronic renal failure.
    Spustová V; Gajdos M; Opatrný K; Stefíková K; Dzúrik R
    Physiol Res; 1991; 40(6):599-606. PubMed ID: 1811729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
    Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
    Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transport of small, middle, and large molecular weight substances in a dual filtration artificial kidney.
    Smeby LC; Jörstad S; Wideröe TE; Svartaas TM
    Artif Organs; 1981; 4 Suppl():104-9. PubMed ID: 7295075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum beta-endorphin in non-dialysed and haemodialysed patients with chronic renal failure.
    Trelewicz P; Grzeszczak W; Drabczyk R
    Int Urol Nephrol; 1994; 26(1):117-23. PubMed ID: 8026916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A purification method by uncoated charcoal.
    Cerulli N; Politi L; D'Angelo AR; Scandurra R
    Adv Exp Med Biol; 1987; 223():193-6. PubMed ID: 3447435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.